

## 16894 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

Board Certification: American Board of Internal Medicine, February 30, 1950.  
State Licensure:

Connecticut—Medicine and Surgery, February 1945 No. 4994.  
Indiana—Medicine, Surgery and Obstetrics, June 1971, No. 23551.  
New York—Medicine and Surgery, June 1945, No. 43171.  
Oklahoma—Medicine and Surgery, December, 1952, No. 6365.  
Tennessee—Medicine and Surgery, 1946.

Committee Memberships and Other Appointments:

Section on Cardiovascular Physiology, Committee on Cardiovascular Disease, American College of Chest Physicians, 1957-60.

Board of Directors, American Society for the Study of Arteriosclerosis, 1956-59.

American Heart Association.

Fellow, Council on Arteriosclerosis.

Credentials Committee, 1958-60.

Program Committee, 1959-64.

Publications Committee, 1960-70.

Research Committee, 1960.

Secretary-Treasurer, 1962-63.

Vice Chairman, 1963-64.

Chairman, 1964-65.

Medical Education, 1966-

Cerebrovascular Disease, 1966-

Subcommittee to Revise Rules and Regulations, 1968.

Cardiovascular O Research Study Committee, 1971-74.

Council on Thrombosis, 1971.

Board of Directors, A.H.A.

Member, Executive Committee.

Member, Central Committee.

Research Committee of the Oklahoma Heart Association, 1957-68.

Board of Directors, Oklahoma Heart Association, 1959-70.

Executive Committee, Oklahoma Heart Association, 1963-70.

President, Oklahoma Heart Association, 1967-68.

Chairman, Committee for U.S.P.H.S. Area Cardiovascular Grant (H-1889), University of Oklahoma Medical Center, 1957-64.

General Advisory and Supervisory Committee for Special Procedures Laboratory, Mercy Hospital, Oklahoma City, 1959-60.

Cardiovascular Study Section, National Heart Institute, N.I.H., 1960-63.

Council Member, Central Society for Clinical Research, 1963-66.

Heart Special Projects Committee, National Heart Institute, N.I.H., 1963-66.

Board of Editors, Journal of Laboratory and Clinical Medicine, 1958-65.

Board of Editors, Circulation, 1966-70.

Board of Editors, Journal of Chronic Diseases, 1966-

Board of Editors, Stroke, 1969-1974.

Board of Managers, Wistar Institute, 1972—Scientific Advisory Committee, 1972.

Scientific Advisory Committee, The Hormel Institute, Austin, Minnesota, 1973-

Council for the Institute of Administration and Management, Union College, Chairman, Curriculum Committee.

Associate Trustee, University of Pennsylvania.

National Research Council, Clinical Sciences Panel.

---

### LILLY TESTIFIES DARVON IS SAFE AND EFFECTIVE

WASHINGTON, D.C.—Eli Lilly and Company's Vice President of Corporate Medical Affairs told a Senate subcommittee today that more than 20 billion doses of the pain killer Darvon have been prescribed over the last 21 years without "a single instance in which the use of propoxyphene products (Darvon's generic name) in accordance with their labeling has caused death or serious injury."

Dr. Robert H. Furman, M.D., the company's representative testified in detail before Senator Gaylord Nelson's Senate Subcommittee on Monopoly and Anti-competitive Activities, and refuted allegations that propoxyphene products such as Darvon were ineffective as analgesics but could cause death.

Dr. Furman pointed out that, contrary to assertions by the Health Research Group, the "findings of several medical authorities, including some who testified